Journal
CLINICAL GENETICS
Volume 83, Issue 3, Pages 212-214Publisher
WILEY
DOI: 10.1111/cge.12050
Keywords
chromatin-modifying enzymes; Kabuki syndrome; KMT2; KMT2B; KMT2D; MLL; MLL2; MLL4; nomenclature
Categories
Funding
- German Federal Ministry of Education and Research (BMBF) [01GM1211A]
Ask authors/readers for more resources
To unravel the system of epigenetic control of transcriptional regulation is a fascinating and important scientific pursuit. Surprisingly, recent successes in gene identification using high-throughput sequencing strategies showed that, despite their ubiquitous role in transcriptional control, dysfunction of chromatin-modifying enzymes can cause very specific human developmental phenotypes. An intriguing example is the identification of de novo dominant mutations in MLL2 as a cause of Kabuki syndrome, a well-known congenital syndrome that is associated with a very recognizable facial gestalt. However, the existing confusion in the nomenclature of the human and mouse MLL gene family impedes correct interpretation of scientific findings for these genes and their encoded proteins. This Review aims to point out this nomenclature pitfall, to explain its historical background, and to promote an unequivocal nomenclature system for chromatin-modifying enzymes as proposed by Allis et al. (2007).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available